Screener
Ligand Pharmaceuticals LGND Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Royalties owed to third parties | $11,356 | $16,202 |
| Professional fees | 8,239 | 1,997 |
| Compensation | 4,635 | 6,388 |
| Value-added tax | 1,824 | 1,753 |
| Subcontractor | 1,756 | 1,756 |
| Accrued interest | 863 | 1,307 |
| Customer deposit | 621 | 621 |
| Other | 2,573 | 1,429 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's accrued expenses?
- Ligand Pharmaceuticals (LGND) reported accrued expenses of $4.64M in Q2 2026.
- How has Ligand Pharmaceuticals's accrued expenses changed year-over-year?
- Ligand Pharmaceuticals's accrued expenses increased by 84.4% year-over-year, from $2.51M to $4.64M.
- What is the long-term trend for Ligand Pharmaceuticals's accrued expenses?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's accrued expenses has grown at a -19.2% compound annual growth rate (CAGR), from $18.53M to $6.39M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Ligand Pharmaceuticals's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude